Quantcast

Latest Eisai Co. Ltd. Stories

2012-01-18 04:20:01

Tokyo, Jan 18, 2012 - (JCN Newswire) - Eisai Co. Ltd announced today that it received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on January 18, 2012 to market Lunesta (eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc., "Sepracor"; a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd), has been marketed in the...

2012-01-16 04:20:01

Tokyo, Jan 16, 2012 - (JCN Newswire) - Nobelpharma Co. Ltd and Eisai Co. Ltd announced today that they will launch the anticonvulsant agent Fostoin 750 mg for Injection (fosphenytoin sodium hydrate, "fostoin") on January 17. Developed in Japan by Nobelpharma, Fostoin will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used both in Japan and overseas as...

2011-12-26 00:20:01

Tokyo, Dec 26, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA receptor antagonist perampanel for partial-onset seizures associated with epilepsy to the U.S. Food and Drug Administration (FDA) on December 22, 2011 (U.S. eastern standard time). This resubmission comes after the FDA issued a Refusal to File letter in July 2011 in which FDA requested reformatting and reanalyses of some datasets in the dossier....

2011-12-21 04:20:01

Tokyo, Dec 21, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co. Ltd submitted an application for partial change to the approved label for egg white lysozyme preparation Neuzym to Japan's Ministry of Health, Labour and Welfare (MHLW) on December 21, 2011. The company is seeking approval to remove alveolar pyorrhea and other conditions as approved indications for the product as well as to make changes to dosage and...

2011-12-15 00:20:01

Tokyo, Dec 15, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited (Eisai Canada) has received approval from Health Canada for Halaven (eribulin mesylate), a novel anticancer agent discovered and developed by Eisai, for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an...

2011-12-13 04:20:01

Tokyo, Dec 13, 2011 - (JCN Newswire) - Eisai Co. Ltd today submitted a marketing and manufacturing authorization application to Japan's Ministry of Health, Labour and Welfare seeking approval of a new dry syrup formulation of its Alzheimer's disease (AD) treatment Aricept (donepezil hydrochloride).In August 2007, the indication of Aricept was expanded to include severe AD. The simultaneous approval of additional dosage, which states that once daily dosage of donepezil hydrochloride may be...

2011-12-02 00:20:01

Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics Tokyo, Dec 2, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that the company's U.S. research subsidiary H3 Biomedicine held a ceremony on December 1 (U.S. Eastern Standard Time) in Massachusetts, Cambridge, to mark the official opening and commencement of operations of its new research facility. H3 Biomedicine aims to...

2011-12-01 00:20:01

Tokyo, Dec 1, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited held a ceremony on November 30 (local time in Toronto) to celebrate its official opening and entry into the Canadian healthcare marketplace.Eisai Canada was established in Mississauga, Ontario, one of largest biopharmaceutical clusters and medical communities in North America, in April 2010 as Eisai's first pharmaceutical sales base for the Canadian market....

2011-11-30 00:20:01

Tokyo, Nov 30, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Warfarin Granules 0.2%, a new formulation of the company's oral anti-coagulant Warfarin (warfarin potassium), on December 1 in Japan.Warfarin Granules 0.2% received marketing authorization in Japan on July 15 of this year and was subsequently listed on Japan's National Health Insurance (NHI) drug price list on November 28. This new formulation is designed to help patients who find it difficult to...

2011-11-18 00:20:01

Tokyo, Nov 18, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that it has entered into a Japan co-promotion agreement with Novartis Pharma K.K. for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD). These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related